Abstract
According to recent experience there is an unexpected high prevalence of treatment resistance in hypertension, i.e. an inefficiency of even complex treatment modalities, increasing the need for multi-drug regimens. Mostly, this applies to systolic hypertension which over the years was found to cause at least as much target organ damage as diastolic. In view of the high prevalence of hypertension, such resistance may be a rising concern. This might not only be due to inefficiency of drugs, but also to low blood pressure levels as treatment goals and to increasing patient age with more systolic hypertension. Over the past few years, some new evidence has accumulated that will contribute to a break-down of the complex of treatment resistance into several categories of both primary and secondary hypertension, the most important may be the high frequency of white-coat hypertension, aldosteronism, low-renin hypertension and adiposity. In turn, the new evidence may lead to effective treatment for nearly every patient suffering therapy resistance. Such efficiency is all the more wanted since blood pressures in these patients are often severe and fraught with serious complications.
Keywords: Aldosteronism, amiloride, guidelines, low-renin, randomized, refractory, trials
Current Drug Therapy
Title: An Increasing Incidence of Treatment Resistance in Hypertension?
Volume: 1 Issue: 3
Author(s): Ivar K. Eide
Affiliation:
Keywords: Aldosteronism, amiloride, guidelines, low-renin, randomized, refractory, trials
Abstract: According to recent experience there is an unexpected high prevalence of treatment resistance in hypertension, i.e. an inefficiency of even complex treatment modalities, increasing the need for multi-drug regimens. Mostly, this applies to systolic hypertension which over the years was found to cause at least as much target organ damage as diastolic. In view of the high prevalence of hypertension, such resistance may be a rising concern. This might not only be due to inefficiency of drugs, but also to low blood pressure levels as treatment goals and to increasing patient age with more systolic hypertension. Over the past few years, some new evidence has accumulated that will contribute to a break-down of the complex of treatment resistance into several categories of both primary and secondary hypertension, the most important may be the high frequency of white-coat hypertension, aldosteronism, low-renin hypertension and adiposity. In turn, the new evidence may lead to effective treatment for nearly every patient suffering therapy resistance. Such efficiency is all the more wanted since blood pressures in these patients are often severe and fraught with serious complications.
Export Options
About this article
Cite this article as:
Eide K. Ivar, An Increasing Incidence of Treatment Resistance in Hypertension?, Current Drug Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157488506778194893
DOI https://dx.doi.org/10.2174/157488506778194893 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology Effects of Compounds from Passiflora edulis Sims f. flavicarpa Juice on Blood Coagulation and on Proteolytic Enzymes
Protein & Peptide Letters Obstructive Sleep Apnea and Cardiovascular Disease - A New Target for Treatment
Current Pharmaceutical Design Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation
Current Drug Discovery Technologies Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review
Current Diabetes Reviews Epidural Analgesia in the Post-Anaesthesia Care Unit
Current Drug Targets Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Vascular Dysfunction in the Brain; Implications for Heavy Metal Exposures
Current Hypertension Reviews Mechanism and Anticancer Activity of the Metabolites of an Endophytic Fungi from Eucommia ulmoides Oliv
Anti-Cancer Agents in Medicinal Chemistry Hormonal Status Modifies Renin-Angiotensin System-Regulating Aminopeptidases andVasopressin-DegradingActivity in the Hypothalamus-Pituitary-Adrenal Axis of Female Mice
Medicinal Chemistry Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Synthesis of Benzothiazolyl Guanidinyl Derivatives and their In-Vitro Antimicrobial and Antioxidant Activity
The Natural Products Journal Development and Validation of a Sensitive HPLC-MS/MS-ESI Method for Determination of Febuxostat: Application to Pharmacokinetic Study
Current Analytical Chemistry Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology